Abbott Laboratories (ABT)

82.79
NYSE : Health Technology
Prev Close 82.38
Day Low/High 82.03 / 83.32
52 Wk Low/High 65.44 / 88.76
Avg Volume 4.62M
Exchange NYSE
Shares Outstanding 1.77B
Market Cap 145.60B
EPS 1.30
P/E Ratio 50.85
Div & Yield 1.28 (1.51%)

Latest News

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

U.S. Monetary Policy, Trading Lockheed, Netflix and United Rentals: Market Recon

U.S. Monetary Policy, Trading Lockheed, Netflix and United Rentals: Market Recon

Preventing the U.S. dollar from appreciating too aggressively while repairing credit conditions are 'job freaking one'.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Jim Cramer: These 7 True Laggards Have Caught Fire

Jim Cramer: These 7 True Laggards Have Caught Fire

These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.

Good News From China, Plus Netflix Earnings and Playing CSX: Market Recon

Good News From China, Plus Netflix Earnings and Playing CSX: Market Recon

China reported positive data, bolstering markets. Netflix had a beat on earnings, but faces fierce competition ahead. CSX is a thing of beauty.

Trading Notes for Select Stocks

Trading Notes for Select Stocks

Here's my take on a list of stocks I've been watching.

Shares of Abbott Laboratories Poised for Upside Breakout

Shares of Abbott Laboratories Poised for Upside Breakout

ABT is pointed up after trading in a choppy range since October.

An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon

An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon

Keeping an eye on the Senate shutdown vote and any trade discussion today, and watching key support levels on the SPX.

Jim Cramer: If We Get a China Deal, Then This Rally Is In Its Infancy

Jim Cramer: If We Get a China Deal, Then This Rally Is In Its Infancy

The kick will come from the Chinese capitulating because their economy is so weak.

New Favorites for 2019 from Last Year's Top Stock Pickers

New Favorites for 2019 from Last Year's Top Stock Pickers

Mike Cintolo and Jim Woods saw their top picks for 2018 rise 81% and 75%, respectively.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Why Netflix Is a Good Name to Short on This Earnings Report: Market Recon

Why Netflix Is a Good Name to Short on This Earnings Report: Market Recon

I am unimpressed by the latest earnings report. Despite good subscriber growth, fundamentals look weak.

Abbott Rated New Overweight at Barclays

Sell Abbott Laboratories Down to a 'Sleeping Position'

Sell Abbott Laboratories Down to a 'Sleeping Position'

While Abbott's charts are not screaming sells, there are enough signals to suggest a cautious approach to earnings.

Jim Cramer: Know Which Way the Wind Blows Before You Pick Stocks

Jim Cramer: Know Which Way the Wind Blows Before You Pick Stocks

PepsiCo, GE and just like the weather, the stock market is subject to change.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Jim Cramer: Valuations Now Have No Relation to Common Sense

Jim Cramer: Valuations Now Have No Relation to Common Sense

Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Sector Rotation Is Powerful: This Tech Hit Is a Great Trade

Sector Rotation Is Powerful: This Tech Hit Is a Great Trade

As hedge funds are forced to unwind tech positions, here is how to play the rotation.

Pullback in Abbott Labs Gives Buyers Another Chance

Pullback in Abbott Labs Gives Buyers Another Chance

Our latest analysis and strategy on ABT shares.

Jim Cramer: Trade Wars and Tariffs May Soon Be Baked Into Pricing

Jim Cramer: Trade Wars and Tariffs May Soon Be Baked Into Pricing

Earnings have been strong, and analysts will soon start to concentrate more on actual weakness than shadow-boxing weakness.

Abbott Laboratories Gaps to the Upside in a Classic Breakout

Abbott Laboratories Gaps to the Upside in a Classic Breakout

If you are long ABT continue to hold and raise sell stop protection to a close below $59 or where the 200-day moving average line intersects.

Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon

Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon

This group is expected to post second-quarter EPS gains of 30%; here is how to trade it.

Medical Device Stocks Could Be Gearing Up to Be Market Leaders

Medical Device Stocks Could Be Gearing Up to Be Market Leaders

When chartists look for the next market leaders they often go to stocks that have held up the best during corrections.

Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits

Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits

When rates decline, most of the S&P 500 benefits, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.